Entry Name Hepatitis C
Description Hepatitis C virus (HCV) is a major cause of chronic liver disease. The HCV employ several strategies to perturb host cell immunity. After invasion, HCV RNA genome functions directly as an mRNA in the cytoplasm of the host cell and forms membrane-associated replication complexes along with non-structural proteins. Viral RNA can trigger the RIG-I pathway and interferon production during this process. Translated HCV protein products regulate immune response to inhibit the action of interferon. HCV core and NS5A proteins appear to be the most important molecules with regulatory functions that modulate transcription, cellular proliferation, and apoptosis.
Class Human Diseases; Infectious disease: viralBRITE hierarchy
Pathway map Disease Drug D00423 Ribavirin (JP18/USP/INN)
D03433 Celgosivir hydrochloride (USAN)
D06651 Taribavirin hydrochloride (USAN)
D09012 Telaprevir (JAN/USAN/INN)
D09028 Valopicitabine dihydrochloride (USAN)
D09583 Balapiravir hydrochloride (USAN)
D09885 Danoprevir sodium (USAN)
D09987 Vaniprevir (JAN/USAN/INN)
D10105 Daclatasvir dihydrochloride (USAN)
D10366 Sofosbuvir (JAN/USAN/INN)
D10394 Deldeprevir sodium (USAN)
D10462 Faldaprevir sodium (JAN/USAN)
D10469 Simeprevir sodium (JAN)
D10477 Mericitabine (USAN/INN)
D10578 Ledipasvir and sofosbuvir
D10580 Paritaprevir (USAN/INN)
D10581 Dasabuvir sodium hydrate
D10582 Dasabuvir, ombitasvir, paritaprevir and ritonavir
D10597 Paritaprevir hydrate (JAN)
D10598 Ombitasvir hydrate (JAN)
D10599 Ledipasvir acetonate (JAN)
D10611 Beclabuvir hydrochloride (JAN/USAN)
D10622 Deleobuvir sodium (JAN/USAN)
D10625 Elbasvir (JAN/USAN/INN)
D10745 Ombitasvir, paritaprevir and ritonavir
D10778 Elbasvir and grazoprevir
D10806 Velpatasvir (JAN/USAN/INN)
D10815 Glecaprevir hydrate (JAN)
D10816 Pibrentasvir (JAN/USAN/INN)
D10882 Daclatasvir, asunaprevir and beclabuvir
D10899 Voxilaprevir (USAN/INN)
D10900 Sofosbuvir, velpatasvir and voxilaprevir
D10996 Uprifosbuvir (USAN/INN)
D12260 Bemnifosbuvir sulfate (USAN)
D12745 Ravidasvir hydrochloride (USAN)
Orthology K00922 PIK3CA_B_D; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha/beta/delta [EC:2.7.1.153 ]
K02084 APAF1; apoptotic protease-activating factor
K02158 BAD; Bcl-2-antagonist of cell death
K02159 BAX; apoptosis regulator BAX
K02373 FADD; FAS-associated death domain protein
K02580 NFKB1; nuclear factor NF-kappa-B p105 subunit
K02649 PIK3R1_2_3; phosphoinositide-3-kinase regulatory subunit alpha/beta/delta
K02861 RIPK1, RIP1; receptor-interacting serine/threonine-protein kinase 1 [EC:2.7.11.1 ]
K03156 TNF, TNFA; tumor necrosis factor superfamily, member 2
K03158 TNFRSF1A, TNFR1, CD120a; tumor necrosis factor receptor superfamily member 1A
K03171 TRADD; tumor necrosis factor receptor type 1-associated DEATH domain protein
K03174 TRAF3; TNF receptor-associated factor 3
K03237 EIF2S1; translation initiation factor 2 subunit 1
K03250 EIF3E, INT6; translation initiation factor 3 subunit E
K03456 PPP2R1; serine/threonine-protein phosphatase 2A regulatory subunit A
K04354 PPP2R2; serine/threonine-protein phosphatase 2A regulatory subunit B
K04357 EGF; epidermal growth factor
K04364 GRB2; growth factor receptor-bound protein 2
K04365 BRAF; B-Raf proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1 ]
K04366 RAF1; RAF proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1 ]
K04368 MAP2K1, MEK1; mitogen-activated protein kinase kinase 1 [EC:2.7.12.2 ]
K04369 MAP2K2, MEK2; mitogen-activated protein kinase kinase 2 [EC:2.7.12.2 ]
K04377 MYC; Myc proto-oncogene protein
K04382 PPP2C; serine/threonine-protein phosphatase 2A catalytic subunit [EC:3.1.3.16 ]
K04389 TNFSF6, FASL, CD178; tumor necrosis factor ligand superfamily member 6
K04390 TNFRSF6, FAS, CD95; tumor necrosis factor receptor superfamily member 6
K04451 TP53, P53; tumor protein p53
K04467 IKBKA, IKKA, CHUK; inhibitor of nuclear factor kappa-B kinase subunit alpha [EC:2.7.11.10 ]
K04503 CCND1; G1/S-specific cyclin-D1
K04692 STAT3; signal transducer and activator of transcription 3
K04693 IRF9, ISGF3G, P48; interferon regulatory factor 9
K04696 SOCS3, CIS3; suppressor of cytokine signaling 3
K04706 PIAS1; E3 SUMO-protein ligase PIAS1 [EC:2.3.2.-]
K04724 CFLAR, FLIP; CASP8 and FADD-like apoptosis regulator
K04726 BID; BH3 interacting domain death agonist
K04734 NFKBIA; NF-kappa-B inhibitor alpha
K04735 RELA; transcription factor p65
K05130 IFNAR1; interferon receptor 1
K05131 IFNAR2; interferon receptor 2
K05401 TLR3, CD283; toll-like receptor 3
K05411 IRF3; interferon regulatory factor 3
K05842 TRIF; toll-like receptor adapter molecule 1
K06508 CD81, TAPA1, TSPAN28; CD81 antigen
K06618 RB1; retinoblastoma-associated protein
K06620 E2F3; transcription factor E2F3
K06625 CDKN1A, P21, CIP1; cyclin-dependent kinase inhibitor 1A
K06630 YWHAE; 14-3-3 protein epsilon
K06698 PSME3; proteasome activator subunit 3 (PA28 gamma)
K07209 IKBKB, IKKB; inhibitor of nuclear factor kappa-B kinase subunit beta [EC:2.7.11.10 ]
K07210 IKBKG, IKKG, NEMO; inhibitor of nuclear factor kappa-B kinase subunit gamma
K07211 IKBKE, IKKE; inhibitor of nuclear factor kappa-B kinase subunit epsilon [EC:2.7.11.10 ]
K07294 NR1C1, PPARA; peroxisome proliferator-activated receptor alpha
K07827 KRAS, KRAS2; GTPase KRas
K08524 RXRA, NR2B1; retinoid X receptor alpha
K08536 NR1H3, LXRA; liver X receptor alpha
K08845 ARAF, ARAF1; A-Raf proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1 ]
K08860 EIF2AK3, PERK; eukaryotic translation initiation factor 2-alpha kinase 3 [EC:2.7.11.1 ]
K09389 E2F2; transcription factor E2F2
K09447 IRF7; interferon regulatory factor 7
K11220 STAT1; signal transducer and activator of transcription 1
K11221 STAT2; signal transducer and activator of transcription 2
K12473 LDLR; low-density lipoprotein receptor
K12646 RIGI, DDX58; ATP-dependent RNA helicase DDX58 [EC:5.6.2.6 ]
K12648 MAVS, IPS1; mitochondrial antiviral-signaling protein
K12671 CXCL10, IP10; C-X-C motif chemokine 10
K13885 SCARB1; scavenger receptor class B, member 1
K14021 BAK, BAK1; Bcl-2 homologous antagonist/killer
K14217 IFIT1; interferon-induced protein with tetratricopeptide repeats 1
K14754 MX; interferon-induced GTP-binding protein Mx
K15045 RSAD2; radical S-adenosyl methionine domain-containing protein 2
K16194 EIF2AK1; eukaryotic translation initiation factor 2-alpha kinase 1 [EC:2.7.11.1 ]
K16195 EIF2AK2; eukaryotic translation initiation factor 2-alpha kinase 2 [EC:2.7.11.1 ]
K16196 EIF2AK4; eukaryotic translation initiation factor 2-alpha kinase 4 [EC:2.7.11.1 ]
K16197 YWHAB_Q_Z; 14-3-3 protein beta/theta/zeta
K16198 YWHAG_H; 14-3-3 protein gamma/eta
K17454 E2F1; transcription factor E2F1
K22271 Core; Hepatitis C virus core protein
K22272 E2; Hepatitis C virus envelope glycoprotein E2
K22274 NS4A; Hepatitis C virus non-structural protein 4A
K22275 NS5A; Hepatitis C virus non-structural protein 5A
K22472 NS5B; Hepatitis C virus RNA-dependent RNA polymerase [EC:2.7.7.48 ]
K22497 NS2; Hepatitis C virus non-structural protein 2 [EC:3.4.22.-]
K22498 NS4B; Hepatitis C virus non-structural protein 4B
K24861 E1; Hepatitis C virus envelope glycoprotein E1
Compound C05981 Phosphatidylinositol-3,4,5-trisphosphate
Reference Authors Hassan M, Selimovic D, El-Khattouti A, Ghozlan H, Haikel Y, Abdelkader O
Title Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.
Journal Reference Authors Yamauchi Y, Helenius A
Title Virus entry at a glance.
Journal Reference Authors Feneant L, Levy S, Cocquerel L
Title CD81 and hepatitis C virus (HCV) infection.
Journal Reference Authors Dubuisson J, Helle F, Cocquerel L
Title Early steps of the hepatitis C virus life cycle.
Journal Reference Authors Liang TJ, Ghany MG
Title Current and future therapies for hepatitis C virus infection.
Journal Reference Authors Scheel TK, Rice CM
Title Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.
Journal Reference Authors Holmes JA, Thompson AJ
Title Interferon-free combination therapies for the treatment of hepatitis C: current insights.
Journal Reference Authors Taguchi T, Nagano-Fujii M, Akutsu M, Kadoya H, Ohgimoto S, Ishido S, Hotta H
Title Hepatitis C virus NS5A protein interacts with 2',5'-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner.
Journal Reference Authors Horner SM, Gale M Jr
Title Intracellular innate immune cascades and interferon defenses that control hepatitis C virus.
Journal Reference Authors Lemon SM
Title Induction and evasion of innate antiviral responses by hepatitis C virus.
Journal Reference Authors Horner SM, Gale M Jr
Title Regulation of hepatic innate immunity by hepatitis C virus.
Journal Reference Authors Ortega-Prieto AM, Dorner M
Title Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection.
Journal Reference Authors Yang DR, Zhu HZ
Title Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?
Journal Reference Authors Gale M Jr, Foy EM
Title Evasion of intracellular host defence by hepatitis C virus.
Journal Reference Authors Bode JG, Brenndorfer ED, Haussinger D
Title Subversion of innate host antiviral strategies by the hepatitis C virus.
Journal Reference Authors Panteva M, Korkaya H, Jameel S
Title Hepatitis viruses and the MAPK pathway: is this a survival strategy?
Journal Reference Authors Pang R, Tse E, Poon RT
Title Molecular pathways in hepatocellular carcinoma.
Journal Reference Authors Macdonald A, Harris M
Title Hepatitis C virus NS5A: tales of a promiscuous protein.
Journal Reference Authors He Y, Staschke KA, Tan SL
Title HCV NS5A: A Multifunctional Regulator of Cellular Pathways and Virus Replication
Journal Hepatitis C Viruses: Genomes and Molecular Biology (2006)
Reference Authors Lan KH, Sheu ML, Hwang SJ, Yen SH, Chen SY, Wu JC, Wang YJ, Kato N, Omata M, Chang FY, Lee SD
Title HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis.
Journal Reference Authors Majumder M, Ghosh AK, Steele R, Zhou XY, Phillips NJ, Ray R, Ray RB
Title Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice.
Journal Reference Authors Hassan M, Ghozlan H, Abdel-Kader O
Title Activation of RB/E2F signaling pathway is required for the modulation of hepatitis C virus core protein-induced cell growth in liver and non-liver cells.
Journal Reference Authors Kwun HJ, Jung EY, Ahn JY, Lee MN, Jang KL
Title p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3.
Journal Reference Authors Yamanaka T, Uchida M, Doi T
Title Innate form of HCV core protein plays an important role in the localization and the function of HCV core protein.
Journal Reference Authors Lim EJ, Chin R, Angus PW, Torresi J
Title Enhanced apoptosis in post-liver transplant hepatitis C: effects of virus and immunosuppressants.
Journal Reference Authors Fischer R, Baumert T, Blum HE
Title Hepatitis C virus infection and apoptosis.
Journal Reference Authors Saito K, Meyer K, Warner R, Basu A, Ray RB, Ray R
Title Hepatitis C virus core protein inhibits tumor necrosis factor alpha-mediated apoptosis by a protective effect involving cellular FLICE inhibitory protein.
Journal Reference Authors Koike K
Title Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection.
Journal Reference Authors Tanaka N, Moriya K, Kiyosawa K, Koike K, Aoyama T
Title Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor alpha in transgenic mice: implications for HCV-associated hepatocarcinogenesis.
Journal Reference Authors Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ
Title Viral hepatocarcinogenesis: from infection to cancer.
Journal Related ko04620 Toll-like receptor signaling pathway
ko04622 RIG-I-like receptor signaling pathway
